Highbridge Capital Management’s Integra LifeSciences IART Stock Holding History

Highbridge Capital Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-36,865	Closed	-$1.55M	–	1409
2017 Q1	$1.55M	Buy	+36,865	New	+$1.58M	0.02%	496
2016 Q4	–	Sell	-8,140	Closed	-$336K	–	1411
2016 Q3	$336K	Buy	+8,140	New	+$341K	0.01%	970
2015 Q4	–	Sell	-23,750	Closed	-$708K	–	1619
2015 Q3	$708K	Buy	+23,750	New	+$743K	0.01%	910

Other funds holding IART

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Highbridge Capital Management's IART Position: Q2 2017 in Review

Highbridge Capital Management sold out of Integra LifeSciences (IART) in Q2 2017, closing a stake of 36,865 shares — an estimated $1.55M sold.

Highbridge Capital Management first reported a position in IART in Q3 2015 and held it in 3 quarters. The position peaked at $1.55M in Q1 2017. 223 funds tracked by Wall St. Rank hold IART as of Q2 2017.

Highbridge Capital Management reported no remaining Integra LifeSciences position as of Q2 2017 after selling out during the quarter.
Highbridge Capital Management sold 36,865 Integra LifeSciences shares in Q2 2017, an estimated $1.55M.
Highbridge Capital Management first reported a position in Integra LifeSciences in Q3 2015 and held it in 3 quarters.
Highbridge Capital Management's Integra LifeSciences position peaked at $1.55M in Q1 2017.
223 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.